Viking Therapeutics Prepares to Defend Its Obesity Trial Timeline Against Growing Skepticism

Viking Therapeutics reports second-quarter 2026 earnings after the close on July 29, with Wall Street bracing for a loss of $1.21 per share—more than double the year-ago deficit. The biotech's shares have come under pressure in recent weeks as investors weigh mounting clinical trial costs and a widening cash burn against the promise of its obesity and metabolic disease pipeline. With analyst sentiment deteriorating and the options market pricing a 9% post-earnings swing, this report will test whether VKTX can maintain confidence in its development timeline or whether concerns about runway and dilution will dominate the narrative.

Part 1: Earnings Preview

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, with lead programs targeting obesity, non-alcoholic steatohepatitis (NASH), and X-linked adrenoleukodystrophy. The company's pipeline centers on VK2735, a dual GLP-1/GIP receptor agonist competing in the crowded obesity space, and VK0214, a thyroid hormone receptor beta agonist for NASH.

Viking is expected to report second-quarter results after the close on July 29, with the consensus calling for a loss of $1.21 per share on no revenue. The most recently reported quarter (Q1 2026) delivered a loss of $1.37 per share, significantly worse than the $0.95 estimate. Year-over-year, the expected Q2 loss of $1.21 compares to a loss of $0.58 in the same quarter last year, reflecting a 109% deterioration as the company ramps spending on pivotal trials.

Three key themes define this earnings story:

1. Clinical Trial Execution and Timeline Visibility: Investors are laser-focused on updates to the VK2735 Phase 2 obesity trial and any guidance on pivotal study initiation. The market is hungry for data readouts and regulatory pathway clarity, particularly as competitors advance their own GLP-1 programs. Any delay or lack of specificity could trigger selling pressure.

2. Cash Runway and Financing Needs: With losses widening sharply—Q1's $1.37 miss was 44% worse than expected—the Street is increasingly concerned about how long Viking's balance sheet can support its ambitious development plans. Investors will scrutinize cash burn guidance and any signals about potential capital raises, which could dilute existing shareholders.

3. Competitive Positioning in Obesity: The obesity drug landscape has become intensely competitive, with established players and well-funded biotechs vying for market share. Viking must articulate how VK2735's profile—efficacy, safety, dosing convenience—differentiates it from the pack, especially as investor enthusiasm for "me-too" GLP-1 programs has cooled.

Analyst commentary ahead of the release reflects growing caution. While the majority of the 20 analysts covering VKTX maintain buy ratings (17 Strong Buys), one analyst recently downgraded to a Strong Sell, and sentiment has deteriorated over the past month. The consensus price target of $88.50 implies substantial upside from current levels, but the widening gap between estimates and actual results—four consecutive quarters of misses—has eroded confidence. Analysts are emphasizing the need for Viking to deliver concrete clinical milestones and demonstrate disciplined capital allocation to justify its valuation in an increasingly skeptical market.

Part 2: Historical Earnings Performance

Viking Therapeutics has established a troubling pattern of consistent and significant earnings misses over the past four quarters. The company has missed consensus estimates in every report since June 2025, with shortfalls ranging from 16% to 55%. Most recently, Q1 2026 delivered a loss of $1.37 per share against a $0.95 estimate—a 44% miss—while Q4 2025 came in at $1.38 versus $0.89 expected, a 55% miss.

The magnitude of these misses has been escalating. The two most recent quarters (Q4 2025 and Q1 2026) posted the largest negative surprises in the dataset, both exceeding 40%. This compares to more modest misses of 16% and 32% in the prior two quarters. The pattern suggests either overly optimistic analyst modeling, faster-than-anticipated spending on clinical programs, or both.

Year-over-year comparisons underscore the deterioration: losses have more than doubled from $0.58 in Q2 2025 to an expected $1.21 in Q2 2026. The trend is clear—as Viking advances its pipeline toward pivotal trials, cash burn is accelerating faster than the Street has been able to model, creating a credibility gap that will be difficult to close without either a significant clinical catalyst or a reset of expectations.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Viking Therapeutics reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.

Historical price action around Viking's earnings has been volatile and directionally inconsistent, with an average absolute Day 0 move of 2.79% and a much larger Day +1 average of 8.96%. The Day +1 range averages 13.39%, indicating substantial intraday swings as investors process the results and management commentary.

The most dramatic moves occurred in the second half of 2024, when the stock surged over 20% on Day +1 following both the July and October reports, likely driven by positive clinical trial updates that overshadowed the earnings misses. More recently, however, the pattern has been choppier: the April 2026 report saw a modest 3.3% Day 0 decline with minimal follow-through, while February 2026 posted a 6.8% Day +1 rally after an initial flat reaction.

The key takeaway: Day +1 moves have been significantly larger and more consequential than Day 0, with the market waiting for the full earnings package—guidance, trial updates, cash burn commentary—before making major directional bets. Investors should expect a wide range of outcomes, with historical precedent for double-digit swings in either direction depending on the clinical and financial narrative management delivers.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 9.19% for the upcoming report, which sits between the historical Day 0 average of 2.79% and the Day +1 average of 8.96%. This suggests options traders are anticipating a reaction closer to the typical Day +1 magnitude, reflecting the after-hours reporting schedule and the likelihood that the real price discovery occurs the following session. The expected move is notably below the 13.39% average Day +1 range, indicating the market may be underpricing potential volatility given Viking's recent history of large post-earnings swings.

Part 3: What Analysts Are Saying

Analyst sentiment on Viking Therapeutics remains predominantly bullish but deteriorating. The consensus rating stands at 4.60 out of 5.00, with 17 of 20 analysts maintaining Strong Buy ratings. However, the picture has darkened recently: one analyst downgraded to a Strong Sell in the past month, and the average recommendation has slipped from 4.70, marking a deteriorated sentiment trend.

The average price target of $88.50 implies 161% upside from the current price of $33.86, with estimates ranging from a high of $125.00 to a low of $31.00. The wide dispersion—spanning nearly $94—reflects deep disagreement about Viking's risk-reward profile. Bulls see transformative potential in the obesity pipeline and assign blockbuster valuations, while the lone bear appears to be pricing in significant execution risk, dilution concerns, or competitive displacement.

The shift in sentiment is notable: a month ago, the Street was more uniformly optimistic with three Hold ratings and zero Sells. The recent downgrade and reduction in Hold ratings to two suggest some analysts are losing patience with the widening losses and lack of near-term catalysts. While the consensus remains constructive, the erosion of confidence—particularly the appearance of the first Strong Sell—signals that Viking is entering a "show me" phase where clinical progress and capital discipline will be critical to maintaining buy-side support.

Part 4: Technical Picture

Viking Therapeutics enters earnings in a weakening technical posture, with the Barchart Technical Opinion registering a 48% Buy signal—unchanged from last week but a sharp deterioration from the 8% Sell signal a month ago. The recent recovery from deeply oversold conditions has stalled, leaving the stock in a precarious position just ahead of the report.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal suggests near-term momentum has stabilized but lacks conviction
• Medium-term (50% Buy): Neutral-to-positive reading indicates the intermediate trend is attempting to find support
• Long-term (50% Buy): Moderate buy signal reflects a longer-term base-building effort after recent weakness

Trend Characteristics: The signal strength is classified as Weak and the direction is Weakening, indicating the technical setup is fragile and vulnerable to further deterioration if earnings disappoint.

At $33.86, Viking is trading below its 5-day ($35.24), 10-day ($36.18), and 20-day ($37.63) moving averages, confirming recent downside momentum. However, the stock remains above its 50-day ($33.79), 100-day ($33.54), and 200-day ($33.82) moving averages, suggesting longer-term support is holding—barely. The stock is essentially sitting on top of its key long-term moving averages, making this earnings report a critical test of whether that support holds or breaks.

The technical setup heading into earnings is cautionary. Viking is trapped below short-term resistance (the 20-day moving average at $37.63) and sitting precariously on long-term support (the 50-, 100-, and 200-day averages clustered near $33.80). A disappointing report could trigger a breakdown through this support zone, while a positive surprise would need to reclaim the 20-day average to signal a meaningful reversal. The weak and weakening trend characteristics suggest the path of least resistance is lower unless management delivers a catalyst strong enough to shift momentum.